Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al

Thyroid. 2021 Feb;31(2):330-331. doi: 10.1089/thy.2020.0245. Epub 2020 Oct 2.
No abstract available

Publication types

  • Comment

MeSH terms

  • Humans
  • Phenylurea Compounds / adverse effects
  • Quinolines* / adverse effects
  • Thyroid Neoplasms* / drug therapy

Substances

  • Phenylurea Compounds
  • Quinolines
  • lenvatinib